Baird Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to $68
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty has maintained an Outperform rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and increased the price target from $57 to $68.
January 30, 2024 | 6:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Joel Beatty maintains an Outperform rating on Ultragenyx Pharmaceutical and raises the price target from $57 to $68.
The increase in price target by Baird reflects a positive outlook on Ultragenyx Pharmaceutical's future performance. This endorsement from a reputable analyst could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100